Field Medical's Presentation at J.P. Morgan Healthcare Conference
Field Medical Inc., a clinical-stage medical technology company, is excited to announce their participation in the prestigious J.P. Morgan Healthcare Conference. The event marks a significant milestone as they showcase innovations in advanced pulsed field ablation (PFA) technology aimed at treating complex cardiac conditions. This presentation will be led by Founding Medical Director, Dr. Steven Mickelsen, highlighting their pioneering work in both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation.
Focus on Advanced Technology
The FieldForce™ Ablation System, designed by Field Medical, plays a crucial role in their presentation. This next-generation platform is engineered to create transmural lesions, offering a revolutionary method for treating VT. As more patients seek effective solutions for cardiac arrhythmias, Field Medical aims to meet this increasing demand through innovative technology.
Overview of the Presentation
During the conference, Field Medical will delve into key topics including a comprehensive company overview and the latest advancements surrounding the FieldForce™ PFA platform. Attendees can expect insights into recent clinical progress in VT and a detailed plan for their upcoming pivotal VT trial. This foundational work sets the stage for future developments in arrhythmia treatments.
Engagement Opportunities
The leadership team at Field Medical will be available for individual meetings throughout the conference. This provides an invaluable opportunity for stakeholders, industry experts, and potential partners to engage directly with the team and learn more about their groundbreaking work. Interested parties are encouraged to connect for a meeting.
In addition to the presentation, discussions will cover accomplishments such as the company’s recent success in earning Breakthrough Device Designation. As Field Medical continues to demonstrate their commitment to innovation, they are eager to connect with others who share a passion for advancing healthcare.
About Field Medical Inc.
Founded in 2022, Field Medical is dedicated to improving therapeutic options for patients with cardiac arrhythmias. Their FieldForce™ Ablation System combines cutting-edge technology with proprietary FieldBending™ energy, ensuring precise and effective ablation methods. To date, the company has made significant strides in developing tools that enhance patient outcomes in ventricular and atrial arrhythmia treatment.
Field Medical’s work has not gone unnoticed, as their recent inclusion in the FDA TAP Pilot Program has positioned them at the forefront of medical technology advancement. Their commitment to research and patient care continues to drive innovation, ensuring that they remain a leader in the industry.
Frequently Asked Questions
What is the FieldForce™ Ablation System?
The FieldForce™ Ablation System is designed for creating transmural lesions to treat conditions like ventricular tachycardia and atrial fibrillation effectively.
Who will present on behalf of Field Medical at the conference?
Dr. Steven Mickelsen, the founder of Field Medical, will lead the presentation at the J.P. Morgan Healthcare Conference.
When is the presentation scheduled?
The presentation is scheduled for the annual J.P. Morgan Healthcare Conference, specifically on January 15, 2026, at 10 a.m. PT.
How can stakeholders meet with Field Medical's team at the conference?
Stakeholders can request meetings by contacting Field Medical’s team through designated channels during the event.
What is the goal of Field Medical's innovations?
Field Medical aims to advance treatment options for complex cardiac arrhythmias through innovative PFA solutions, improving patient outcomes and care.
